Tags

Type your tag names separated by a space and hit enter

Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
Future Cardiol. 2009 Sep; 5(5):453-65.FC

Abstract

Despite the last three decades of progress in improving cardiovascular outcomes via renin-angiotensin-aldosterone system (RAAS) blockade in hypertensive patients, substantial residual morbidity/mortality remains. Attempts to improve clinical outcomes by combining angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have yielded mixed results. Adverse effects of RAAS blockade with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may relate to compensatory increases in plasma renin activity (PRA). The first-in-class direct renin inhibitor, aliskiren, blocks the RAAS at its point-of-activation, suppressing PRA and attenuating increases associated with other antihypertensives. Aliskiren (with or without other agents) provides significant and prolonged blood pressure reductions in a broad range of hypertensive patients and is well tolerated. Initial results from organ-protection studies are promising. Long-term outcomes studies should yield valuable information regarding the significance of direct renin inhibition in clinical practice.

Authors+Show Affiliations

Texas Blood Pressure Institute, Dallas Nephrology Associates, University of Texas Southwestern, Medical Center, 1420 Viceroy Drive, Dallas, TX 75235, USA. ramv@dneph.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19715410

Citation

Ram, C Venkata S.. "Direct Inhibition of Renin: a Physiological Approach to Treat Hypertension and Cardiovascular Disease." Future Cardiology, vol. 5, no. 5, 2009, pp. 453-65.
Ram CV. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. Future Cardiol. 2009;5(5):453-65.
Ram, C. V. (2009). Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. Future Cardiology, 5(5), 453-65. https://doi.org/10.2217/fca.09.31
Ram CV. Direct Inhibition of Renin: a Physiological Approach to Treat Hypertension and Cardiovascular Disease. Future Cardiol. 2009;5(5):453-65. PubMed PMID: 19715410.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. A1 - Ram,C Venkata S, PY - 2009/9/1/entrez PY - 2009/9/1/pubmed PY - 2010/9/30/medline SP - 453 EP - 65 JF - Future cardiology JO - Future Cardiol VL - 5 IS - 5 N2 - Despite the last three decades of progress in improving cardiovascular outcomes via renin-angiotensin-aldosterone system (RAAS) blockade in hypertensive patients, substantial residual morbidity/mortality remains. Attempts to improve clinical outcomes by combining angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have yielded mixed results. Adverse effects of RAAS blockade with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may relate to compensatory increases in plasma renin activity (PRA). The first-in-class direct renin inhibitor, aliskiren, blocks the RAAS at its point-of-activation, suppressing PRA and attenuating increases associated with other antihypertensives. Aliskiren (with or without other agents) provides significant and prolonged blood pressure reductions in a broad range of hypertensive patients and is well tolerated. Initial results from organ-protection studies are promising. Long-term outcomes studies should yield valuable information regarding the significance of direct renin inhibition in clinical practice. SN - 1744-8298 UR - https://www.unboundmedicine.com/medline/citation/19715410/Direct_inhibition_of_renin:_a_physiological_approach_to_treat_hypertension_and_cardiovascular_disease_ L2 - https://www.futuremedicine.com/doi/10.2217/fca.09.31?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -